ZEISS MyoCare and ZEISS MyoCare S continue to significantly slow the progression of myopia according to the latest two-year results from Asia presented at the 2025 annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) at Salt Lake City in the United States.

The meeting heard that the latest one-year results from Europe showed ZEISS MyoCare slows myopia and reduces the risk of fast progression. ZEISS MyoCare lenses were found to be equally effective across both European and Asian children.

The data also confirmed rapid adaptation to ZEISS MyoCare lenses.

Myopia Continues to Slow

In Asian children, after two years of wear, as compared to single vision lenses, ZEISS MyoCare is shown to have slowed myopia progression on average by 0.44D and 0.20 mm and ZEISS MyoCare S by 0.41D and 0.17 mm.1

In White children, after 12 months, ZEISS MyoCare slowed myopia progression on average by 0.21D and 0.14 mm, and significantly reduced the risk of fast progression.2,3 Additionally, ZEISS MyoCare lenses were seen to significantly slow myopia irrespective of past progression.4

The two ongoing multi-centre clinical trials across China and Europe aim to comprehensively evaluate the effectiveness of ZEISS MyoCare lenses to slow myopia.

References available at mivision.com.au.